MedTrace Logo

Results Comparison of Cervical Cancer Early Detection Using Cerviray With VIA Test

NCT06518070 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2024-07-24

No results posted yet for this study

Summary

Cervical cancer, primarily caused by Human Papilloma Virus (HPV), is a significant global health concern, ranking as the fourth most common cancer in women worldwide. In Indonesia, it stands as the second most frequent cancer among women. This study investigates the performance of Cerviray® AI and Cerviray® AI Evaluation, an artificial intelligence (AI) technology for diagnosing cervical cancer, aiming to compare its sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC ROC) with the Visual Inspection with Acetic Acid (VIA) test.

Conditions

Interventions

DIAGNOSTIC_TEST

Cerviray AI

Patient was screened using Cerviray AI, Cerviray AI evaluation by expert anc compared to VIA test in the same day.

Sponsors & Collaborators

  • Universitas Padjadjaran

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2023-10-31
Completion
2023-10-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06518070 on ClinicalTrials.gov